September 29, 2023
4SC receives Orphan Drug Designation (ODD) for resminostat (Kinselby) in CTCL from the US FDA
The US Food and Drug Administration (FDA) has granted Germany based 4SC’s application for Orphan Drug Designation for resminostat (Kinselby) for cutaneous T cell lymphoma (CTCL), the company said in a press release on Wednesday.